Helicobacter pylori infection at long-term treatment by proton pump inhibitors for acid-related diseases (Literature review and resolution of Advisory council, March 22, 2018)

Aim of review. To present management approach for acid-related diseases in patients with Helicobacter pylori (H. pylori) infection, under long-term proton pump inhibitor therapy. Summary. There is no relation of gastroesophageal reflux disease (GERD) symptom severity, the pattern of relapses and treatment efficacy to the presence or absence of H. pylori infection; successful H. pylori eradication does not cause relapse of pre-existing GERD and does not induce its development. At the same time it is impossible to neglect the data on potential induction or aggravation of GERD after H. pylori eradication in separate population groups, including those in Asia. The presence of GERD could not prevent infection eradication in the presence of other indications (e.g., peptic ulcer, chronic gastritis). Monotherapy by proton pump inhibitors (PPI) in H. pylori-positive patients with GERD may lead to progression of gastric corpus atrophy that can be regarded as risk factor for stomach cancer development. H. pylori infection eradication promotes reduction of gastritis-like changes severity irrespective of maintaining of acid-suppressive treatment. The choice of specific PPI for treatment of patients with GERD and other acid-related diseases, carrying out H. pylori eradication therapy or substitution of one PPI agent to another are individualized and depend on the indications registered in the drugs administration instructions, features of its pharmacokinetics and pharmacodynamics, possible drug-to-drug interactions. Conclusion. Testing for H. pylori infection and carrying out the subsequent eradication therapy could allow to prevent progression of corpus mucosa atrophy in patients with acid-related disorders, first of all those with GERD, who received long-term PPI treatment. Estimation of duration of PPI treatment at acid-related disorders, and terms of H. pylori eradication therapy should be evaluated according to clinical guidelines and treatment protocols of these diseases taking into account age of the patient, clinical features, course of disease, presence of complications.

ингибиторы протонной помпы, декслансопразол, гастроэзофагеальная рефлюксная болезнь, Helicobacter pylori, хронический гастрит, атрофический гастрит

1. Wu J.C., Sung J.J., Ng E.K. et al. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East. Am J Gastroenterol 1999; 94 (7):1790-4.

2. Ashktorab H., Entezari O., Nouraie M. et al. Helicobacter pylori protection against reflux esophagitis. Dig Dis Sci 2012; 57 (11):2924-8. doi:10.1007/s10620012-2349-3.

3. Chung S.J., Lim S.H., Choi J. Helicobacter pylori serology inversely correlated with the risk and severity of reflux esophagitis in Helicobacter pylori endemic area: a matched case-control study of 5616 health check-up Koreans. J Neurogastroenterol Motil 2011; 17:267-73.

4. Gashi Z., Sherifi F., Shabani R. The prevalence of Helicobacter pylori infеction in patients with reflux esophagitis our experience. Med Arch 2013; 67(6):402-4. doi: 10.5455/medarch.2013.67.402-4.

5. O’Connor H.J. Review article: Helicobacter pylori and gastro-esophageal reflux disease clinical implications and management. Aliment Pharmacol Ther 1999; 13:117-27.

6. Fishbach L.A., Nordenstedt H., Kramer J.R. et al. The association between Barrett’s esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter 2012; 17:163-75.

7. Rubinstein J.H., Inadomi J.N., Scheiman J. et al. Association between Helicobacter pylori and Barret’s esophagus, erosive esophagitis and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol 2014; 12(2):23945. doi:10.1016/j.cgh.2013.08.029.

8. O’Connor H.J., McGee C., Mehana N., Cunnane K. Prevalence of gastroesopgastroesophageal reflux disease in H.pylori-positive peptic ulcer disease and the impact of eradication therapy. New Orleans:Digestive Disease Week; 1998. Abstracts. PA959.

9. Holtmann G., Cain C.R., Malfertheiner P. The impact of H. pylori on healing of reflux esophagitis during treatment with pantoprazole. Ibid. PA598.

10. De Vires A.C., Kuipers E.J. Helicobacter pylori and nonmalignant diseases. Helicobacter 2010; 15 (Suppl.1):2933. Doi:10.1111/j.1523-5378.2010.00776.x.

11. Polat F.R., Polat S. The effect of Helicоbacter pylori on gastroesophageal reflux disease. JSLS 2012; 16(2):260-3.

12. Wang P.C., Hsu C.S., Tseng T.C. Male sex, hiatus hernia, and Helicobacter pylori infection associated with asymptomatic erosive esophagitis. J Gastroenterol Hepatol 2012; 27 (3):586-91. doi -2011.06881.x.

13. Grande M., Lisi G., De Sanctis F. et al. Does a relationship exist between gastroesophageal reflux and Helicobacter pylori in patients with reflux symptoms? World J Surg Oncol 2014; 12:375. doi: 10.1186?14777819-12-375.

14. Bor S., Kitapcioglu G., Kasar E. Prevalence of gastroesophageal reflux disease in a country with a high occurrence of Helicobacter pylori. World J Gastroenterol 2017; 23 (3):525-32. doi: 10.3748/wjg.v23.i3.525.

15. Kandulski A., Malfertheiner P. Helicobacter pylori and gastroesophageal reflux disease. Cirr Opin Gastroenterol 2014; 30 (4):402-7. doi10.1097/MOG.0000000000000085.

16. Labenz J., Blum A., Bayerdorffer E. et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112 (5):1442-7.

17. Richter J., Falk G.W., Vaezi M.F. Helicobacter pylori and gastroesophageal reflux disease: The bug may not be all bad. Am J Gastroenterol 1998; 93 (10):446-52.

18. Loffeld R.J.L., van der Hulst R.W.H. Helicobacter pylori and gastroesophageal reflux disease: Association and clinical implications. To treat or not to treat with anti-Hp-therapy. Scand J Gastroenterol 2002; 37 (Suppl. 236):15-8.

19. Fallone C.A., Barcun A.N., Friedman G. et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease. Am J Gastroenterol 2000; 95:914-20.

20. Yaghoobi M., Farrokhyar F., Yuan Y., Hunt R.H. Is there an increased risk of GERD after Helicobacter pylori eradication? A meta-analysis. Am J Gastroenterol 2010; 105:1007-13.

21. Malfertheiner P., Megraud F., O’Morain C. et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus report. Gut 2012; 61:646-4. doi: 10.1136/gutjnl-2012-302084.

22. Malfertheiner P., Megraud F., O’Morain C. et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus report. Gut 2016; 0:125. doi: 10.1136/gutjn-2016-312288.

23. Xie T., Cui X., Zheng H., Chen D., He L., Jiang B. Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2013; 25:1195-205.

24. Sheu B.S., Wu M.S., Chiu C.T., Lo J.C., Wu D.C., Liou J.M. et al. Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter 2017; 22(3):

25. Kuipers E.J., Uyterlinde A.M., Pena A.S. et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90:1401-6.

26. Schenk B.E., Kuipers E.J., Nelis S.F. et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46:615-21.

27. Lundell L., Vieth M., Gibson F., Nagy P., Kahrilas P.J. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015; 42:649-63.

28. Song H., Zhu J., Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No.: CD010623. DOI: 10.1002/14651858. CD010623.pub2.

29. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Рос журн гастроэнтерол гепатол колопроктол 2017; 27(4):75-95.

30. Kuipers E.J., Nelis G.F., Klinkenberg-Knol E.C., et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomized controlled trial. Gut 2004;53:12-20.

31. Attwood S.E., Ell C., Galmiche J.P., Fiocca R., Hatlebakk J.G., Hasselgren B., Långström G, Jahreskog M., Eklund S., Lind T., Lundell L. Longterm safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162-74.

32. Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther 2005; 22:193-202.

33. Klinkenberg-Knol E.C., Nelis F., Dent J., Snel P., Mitchell B., Prichard P., Lloyd D., Havu N., Frame M.H., Romàn J., Walan A; Long-Term Study Group. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118(4):661-9.

34. Vigneri S., Termini R., Leandro G., Badalamenti S., Pantalena M., Savarino V. et al. A Comparison of Five Maintenance Therapies for Reflux Esophagitis. N Engl J Med 1995; 333:1106-1110

35. Fiocca R., Mastracci L., Attwood S.E., Ell C., Galmiche J.P., Hatlebakk J. et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012;36(10):959-71.

36. Hallerbäck B., Unge P., Carling L., Edwin B., Glise H., Havu N. et al. Omeprazole or ranitidine in longterm treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994;107(5):1305-11.

37. Genta R.M., Rindi G., Fiocca R., Magner D.J., D’Amico D., Levine D.S. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. Amer J of Gastroenterol 2003;98(6):1257-65.

38. Lundell L., Miettinen P., Myrvold H.E., Pedersen S.A., Thor K., Andersson A. et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999;117(2):319-26.

39. Klinkenberg-Knol E.C., Nelis F., Dent J., Snel P., Mitchell B., Prichard P., Lloyd D., Havu N., Frame M.H., Romàn J., Walan A; Long-Term Study Group. Longterm omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118(4):661-9

40. Ивашкин В.Т., Шептулин А.А., Маев И.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению язвенной болезни. Рос журн гастроэнтерол гепатол колопроктол 2016; 26(6):40-54.

41. Ивашкин В.Т., Маев И.В., Шептулин А.А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии. Рос журн гастроэнтерол гепатол колопроктол 2017; 27(1):50-61.

42. Wedemeyer R.S., Blume H. Pharmacokinetik drug interaction profiles of proton pump inhibitors: an update. Drug Saf 2014; 37(4):201-11.

43. Vakily M., Zhang W., Wy J. et al. Pharmacokinetiks and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009; 25(3):627-38.

44. Behm B.H., Peura D.A. Dexlansoprazole MR for the management of gastroesophageal reflux disease. Exp Rev Gastroenterol Hepatol 2011; 5:439-45.

45. Shin J.M. Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013; 19:25-35.

46. Fass R. et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol 2011; 106(3):421-31.